Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination

Karim Dorgham; Valérie Abadie; Mutsunori Iga; Oliver Hartley; Guy Gorochov; Behazine Combadière

doi:10.1016/j.vaccine.2008.04.003

Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination

Karim Dorgham, Valérie Abadie, Mutsunori Iga, Oliver Hartley, Guy Gorochov, Behazine Combadière

先端分子・細胞治療科

研究成果: Contribution to journal › Article › 査読

13 被引用数 (Scopus)

抄録

Chemokine receptors are promising targets for enhancing T-cell immunity and anti-cancer therapy. CCL5 is a potential adjuvant for DNA vaccination. We postulated that CCR5 superagonists could be even more effective. A CCR5 superagonist derived from natural CCL5 by directed in vitro evolution, namely 1P7, is used as a DNA vaccine adjuvant and expressed as fused chemokine-Ig (1P7-Ig). We show that OVA + 1P7-Ig DNA co-inoculation induced higher frequencies of OVA-specific CD8 lymphocytes than OVA + CCL5-Ig or controls and gave an even better protection against tumor growth in a CCR5-dependant manner. Our results indicate that CCR5-superagonists may provide potent adjuvants for vaccines.

本文言語	英語
ページ（範囲）	3252-3260
ページ数	9
ジャーナル	Vaccine
巻	26
号	26
DOI	https://doi.org/10.1016/j.vaccine.2008.04.003
出版ステータス	出版済み - 6 19 2008

All Science Journal Classification (ASJC) codes

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

文献へのアクセス

10.1016/j.vaccine.2008.04.003

フィンガープリント「Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

@article{06ad9d58e3b6485397a0805b59b97b78,

title = "Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination",

abstract = "Chemokine receptors are promising targets for enhancing T-cell immunity and anti-cancer therapy. CCL5 is a potential adjuvant for DNA vaccination. We postulated that CCR5 superagonists could be even more effective. A CCR5 superagonist derived from natural CCL5 by directed in vitro evolution, namely 1P7, is used as a DNA vaccine adjuvant and expressed as fused chemokine-Ig (1P7-Ig). We show that OVA + 1P7-Ig DNA co-inoculation induced higher frequencies of OVA-specific CD8 lymphocytes than OVA + CCL5-Ig or controls and gave an even better protection against tumor growth in a CCR5-dependant manner. Our results indicate that CCR5-superagonists may provide potent adjuvants for vaccines.",

author = "Karim Dorgham and Val{\'e}rie Abadie and Mutsunori Iga and Oliver Hartley and Guy Gorochov and Behazine Combadi{\`e}re",

note = "Funding Information: This work was supported by the French “Agence Nationale de la Recherche” (ANR “jeunes chercheurs” JC05-4645) and Canc{\'e}ropole Ile-de-France to B.C., the Swiss National Science Foundation (3100A0-11042, O.H.), and the European FP6 “INNOCHEM” and “ATTACK” (Contract: LSHC-CT-2005-018914) programs (G.G.). M.I. was a fellowship recipient of SIDACTION, Paris.",

year = "2008",

month = jun,

day = "19",

doi = "10.1016/j.vaccine.2008.04.003",

language = "English",

volume = "26",

pages = "3252--3260",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "26",

}

TY - JOUR

T1 - Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination

AU - Dorgham, Karim

AU - Abadie, Valérie

AU - Iga, Mutsunori

AU - Hartley, Oliver

AU - Gorochov, Guy

AU - Combadière, Behazine

N1 - Funding Information: This work was supported by the French “Agence Nationale de la Recherche” (ANR “jeunes chercheurs” JC05-4645) and Cancéropole Ile-de-France to B.C., the Swiss National Science Foundation (3100A0-11042, O.H.), and the European FP6 “INNOCHEM” and “ATTACK” (Contract: LSHC-CT-2005-018914) programs (G.G.). M.I. was a fellowship recipient of SIDACTION, Paris.

PY - 2008/6/19

Y1 - 2008/6/19

N2 - Chemokine receptors are promising targets for enhancing T-cell immunity and anti-cancer therapy. CCL5 is a potential adjuvant for DNA vaccination. We postulated that CCR5 superagonists could be even more effective. A CCR5 superagonist derived from natural CCL5 by directed in vitro evolution, namely 1P7, is used as a DNA vaccine adjuvant and expressed as fused chemokine-Ig (1P7-Ig). We show that OVA + 1P7-Ig DNA co-inoculation induced higher frequencies of OVA-specific CD8 lymphocytes than OVA + CCL5-Ig or controls and gave an even better protection against tumor growth in a CCR5-dependant manner. Our results indicate that CCR5-superagonists may provide potent adjuvants for vaccines.

AB - Chemokine receptors are promising targets for enhancing T-cell immunity and anti-cancer therapy. CCL5 is a potential adjuvant for DNA vaccination. We postulated that CCR5 superagonists could be even more effective. A CCR5 superagonist derived from natural CCL5 by directed in vitro evolution, namely 1P7, is used as a DNA vaccine adjuvant and expressed as fused chemokine-Ig (1P7-Ig). We show that OVA + 1P7-Ig DNA co-inoculation induced higher frequencies of OVA-specific CD8 lymphocytes than OVA + CCL5-Ig or controls and gave an even better protection against tumor growth in a CCR5-dependant manner. Our results indicate that CCR5-superagonists may provide potent adjuvants for vaccines.

UR - http://www.scopus.com/inward/record.url?scp=44749086303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44749086303&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.04.003

DO - 10.1016/j.vaccine.2008.04.003

M3 - Article

C2 - 18479788

AN - SCOPUS:44749086303

VL - 26

SP - 3252

EP - 3260

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 26

ER -